文献速递糖尿病

利用纳米载体将1型糖尿病治疗主动靶向至胰腺β细胞

Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers.
PubMed 文献 · Diabetologia · 2025-01-23

本文综述了利用纳米载体实现细胞靶向递送的技术及β细胞靶向领域现状。文章指出,缺乏高特异性β细胞标志物是限制β细胞靶向治疗开发的关键瓶颈,并强调SELEX适配体筛选、噬菌体展示筛选及人类样本组学数据集等技术可用于识别新型β细胞特异性靶点,进而与纳米载体结合实现治疗药物的靶向递送。最终,利用纳米载体的β细胞靶向治疗为开发针对1型糖尿病各阶段的定制疗法提供了独特机会。

要点

  • 外源性胰岛素无法保护残存或替代的β细胞免受免疫介导的死亡。
  • 当前保护β细胞质量或促进其增殖再生的疗法存在脱靶效应,导致剂量需求增加和不良反应。
  • 缺乏高特异性β细胞标志物是β细胞靶向治疗开发的关键瓶颈。

核心结论

  • 利用纳米载体的β细胞靶向治疗为开发针对1型糖尿病各阶段的定制疗法提供了独特机会,目标是提供预防疾病进一步进展或逆转病程的治疗选择。

研究设计与样本

  • 综述,概述了纳米载体用于细胞靶向递送的应用及β细胞靶向领域的现状。

主要发现

  • 外源性胰岛素可维持血糖控制,但不能保护残存或替代的胰腺β细胞免受免疫介导的死亡。
  • 当前旨在保护功能性β细胞质量或促进β细胞增殖和再生的治疗药物可能产生脱靶效应,导致剂量需求增加和不良副作用。
  • 使用纳米载体的靶向药物递送已显示出克服这些局限性的潜力。
  • 缺乏高特异性β细胞标志物是限制β细胞靶向治疗开发的关键瓶颈。

关键数值与推荐

  • SELEX适配体筛选、噬菌体展示筛选和人类样本组学数据集等技术可用于识别新型β细胞特异性靶点,并与纳米载体结合实现治疗药物的靶向递送。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects. Targeted drug delivery using nanocarriers has demonstrated potential for overcoming these limitations. The critical bottleneck limiting the development of beta cell-targeted therapies is a lack of highly specific beta cell markers. This review provides an overview of the use of nanocarriers for cell-targeted delivery and the current state of the field of beta cell targeting. Technologies such as systematic evolution of ligands by exponential enrichment (SELEX) aptamer selection, phage display screening, and omics datasets from human samples are highlighted as tools to identify novel beta cell-specific targets that can be combined with nanocarriers for targeted delivery of therapeutics. Ultimately, beta cell-targeted therapies using nanocarriers present a unique opportunity to develop tailored treatments for each stage of type 1 diabetes with the goal of providing individuals with treatment options that prevent further progression or reverse the course of the disease.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Collins J, Farnsworth NL. Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers. Diabetologia. 2025. PMID: 39847085. doi:10.1007/s00125-024-06356-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。